1. Scrip
  2. >>Business
  3. >>Strategy

Scynexis Prepares To Launch Brexafemme In Vaginal Yeast Infections, Priced At $475

 
• By Joseph Haas

The first-in-class, novel antifungal for vaginal yeast infections will enter a genericized market, but also one with strong demand for better therapeutic options.

Rocket takes off from the hand of the businessman. Concept of start up.
Scynexis is readying launch of its novel anti-fungal for vaginal yeast infections

As Scynexis, Inc. prepares to launch Brexafemme (ibrexafungerp) for vaginal yeast infections in August, the New Jersey firm faces the challenges of a genericized market but also the opportunity of a large patient population eager for new therapeutic options. Given those circumstances, Scynexis CEO Marco Taglietti announced a $475 wholesale acquisition cost (WAC) price for the novel antifungal on 29 June, above the $350-$450 price range he cited upon the product’s US approval on 1 June.

“Setting a WAC price is a complex issue, where you need to listen to the payers, to the doctors and to patients,” Taglietti told Scrip. “In our initial conversations that we started almost two years ago, we had feedback indicating that a price between $350 and $450 was going to be acceptable, but this was based just on a hypothetical description of the [drug] profile

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Q1 S&E In Brief: Tracking New Launches And Catalysts In Biopharma

 
• By Jessica Merrill and Joseph Haas

Neurocrine, Madrigal and Vanda updated investors on new drug launches, while Cytokinetics talked to investors about an FDA extension for aficamten.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

More from Business

Finance Watch: Deerfield Closes $600m-Plus VC Fund; Gates Speeds Up Health Investments

 
• By Mandy Jackson

Private Company Edition: Deerfield’s third innovations fund will back therapeutics and other opportunities, the Gates Foundation – a sometimes funder of biotech firms – will spend $200bn over the next 20 years, and NewLimit raised a $130m series B round, among other financings.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.